DRUG · Unmapped registry intervention
BBT-176, QD
Find medicine records ·
Find other trials using this name
Clinical trial
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
NCT04820023
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
BBT-176, BID
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPhase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
NSCLCverified · MONDO: non-small cell lung carcinoma
Interventions
BBT-176, QDDRUG
BBT-176, BIDDRUG
Sponsors & collaborators
Bridge Biotherapeutics, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04820023 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.